<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00457977</url>
  </required_header>
  <id_info>
    <org_study_id>477</org_study_id>
    <secondary_id>U10HL074424</secondary_id>
    <nct_id>NCT00457977</nct_id>
  </id_info>
  <brief_title>Comparing Two Pneumococcal Vaccines in Adults With Chronic Obstructive Pulmonary Disease</brief_title>
  <acronym>PNEUMO</acronym>
  <official_title>Pneumococcal Vaccine Response in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pneumococcal disease is a serious bacterial infection that can affect different parts of the
      body, including the lungs. People with chronic illnesses, such as chronic obstructive
      pulmonary disease (COPD), have a greater risk of developing pneumonia and meningitis as a
      result of pneumococcal disease. This study will compare the immune response to two types of
      pneumococcal vaccines in adults with COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Individuals who are infected with the Streptococcus pneumoniae bacteria may develop
      pneumococcal disease, a serious disease that kills more people in the United States than all
      other vaccine-preventable diseases combined. Individuals with COPD, characterized by
      breathing difficulties due to damaged and obstructed lung airways, may have an increased risk
      of developing serious complications from pneumococcal disease, including pneumonia and
      meningitis. Currently, there are two types of pneumococcal vaccines available. The
      pneumococcal capsular polysaccharide (CPS) vaccine, known as Pneumovax, is typically given to
      adults 65 years of age or older and to any individuals with a serious health condition,
      including heart disease, lung disease, and diabetes. The diphtheria protein-conjugated
      vaccine (PCV7), known as Prevnar, is typically given to infants; however, adults who receive
      this vaccine may also have a favorable response. The purpose of this study is to compare the
      immune response to the Pneumovax and Prevnar vaccines in adults with COPD.

      This study will enroll adults with mild to moderate COPD. Participants will be randomly
      assigned to receive either the Pneumovax or Prevnar vaccine. This will involve one or two
      injections. Blood collection will occur during study visits at Months 1, 12, and 24. Study
      researchers will contact participants by telephone at Months 6 and 18 to document any
      pneumococcal infections and any additional pneumococcal vaccinations.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serotype Opsonization Titers</measure>
    <time_frame>Measured at Baseline, Months 1, 12, and 24</time_frame>
    <description>Opsonophagocytosis activity (OPK) serotype specific geometric means</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serotype-specific Immunoglobulin G (IgG) Antibody Levels</measure>
    <time_frame>Measured at Baseline, Months 1, 12, and 24</time_frame>
    <description>Serotype-specific immunoglobulin G Geometric Mean IgG antibody levels (ug/ml)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">181</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Pneumovax (PPSV23)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prevnar (PCV7)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Pneumovax (PPSV23)</intervention_name>
    <description>Injection</description>
    <arm_group_label>Pneumovax (PPSV23)</arm_group_label>
    <other_name>23-valent pneumococcal capsular polysaccharide vaccine</other_name>
    <other_name>PPSV23</other_name>
    <other_name>Pneumovax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Prevnar (PCV7)</intervention_name>
    <description>Injection</description>
    <arm_group_label>Prevnar (PCV7)</arm_group_label>
    <other_name>7-valent pneumococcal conjugate vaccine</other_name>
    <other_name>PCV7</other_name>
    <other_name>Prevnar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)

          -  Post-bronchodilator forced expiratory volume at one second

             /forced vital capacity (FEV1/FVC) level less than 70%

          -  Ten or more pack-years of smoking

          -  Willing to make return visits to the study clinic and accept telephone contact

          -  Last pneumococcal vaccination occured at least 5 years prior to study entry

        Exclusion Criteria:

          -  Asthma

          -  Sensitivity to pneumococcal vaccine

          -  Known bleeding disorder, or requires long-term anticoagulation therapy

          -  Presence of chronic disease that may impair pneumococcal vaccine response

          -  Acute illness requiring antibiotics in the month prior to study entry

          -  Medical condition that makes survival for 24 months following study entry unlikely

          -  Pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Antonello Punturieri, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Heart, Lung, and Blood Institute (NHLBI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-0006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LA BioMed at Harbor, University of California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco-Airway Clinical Research Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Health Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204-4507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Medical and Research Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80204-4507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland Hospital</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fallon Clinic</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran's Administration Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HealthPartners Research Foundation</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55440</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Lung Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Emphysema Research Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nih.gov/</url>
    <description>Click here for the National Institutes of Health Web site.</description>
  </link>
  <verification_date>April 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 5, 2007</study_first_submitted>
  <study_first_submitted_qc>April 5, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 9, 2007</study_first_posted>
  <results_first_submitted>March 27, 2014</results_first_submitted>
  <results_first_submitted_qc>April 22, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 12, 2015</results_first_posted>
  <last_update_submitted>April 22, 2015</last_update_submitted>
  <last_update_submitted_qc>April 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Obstructive Pulmonary Disease</keyword>
  <keyword>COPD</keyword>
  <keyword>Pneumococcal</keyword>
  <keyword>Vaccine</keyword>
  <keyword>Opsonization</keyword>
  <keyword>Antibodies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participant's were recruited from 10 medical centers across the US from April 9, 2007 to May 7, 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pneumovax (PPSV23)</title>
          <description>pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)</description>
        </group>
        <group group_id="P2">
          <title>Prevnar (PCV7)</title>
          <description>diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="90"/>
                <participants group_id="P2" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>1-Month</title>
              <participants_list>
                <participants group_id="P1" count="88"/>
                <participants group_id="P2" count="87"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>1-Year</title>
              <participants_list>
                <participants group_id="P1" count="69"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>2-Year</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
                <participants group_id="P2" count="66"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Pneumovax (PPSV23)</title>
          <description>pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)</description>
        </group>
        <group group_id="B2">
          <title>Prevnar (PCV7)</title>
          <description>diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="90"/>
            <count group_id="B2" value="91"/>
            <count group_id="B3" value="181"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="10"/>
                    <measurement group_id="B2" value="63" spread="9"/>
                    <measurement group_id="B3" value="64" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="90"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="181"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced expiratory volume at one second (FEV1)</title>
          <units>LIters (L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.27" spread="0.50"/>
                    <measurement group_id="B2" value="1.33" spread="0.53"/>
                    <measurement group_id="B3" value="1.30" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 (% Predicted)</title>
          <units>percent predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.8" spread="15.1"/>
                    <measurement group_id="B2" value="44.9" spread="14.7"/>
                    <measurement group_id="B3" value="44.8" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>forced expiratory volume at one second/forced vital capacity (FEV1/FVC)</title>
          <units>percentage of FEV1/FVC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.0" spread="12.5"/>
                    <measurement group_id="B2" value="45.8" spread="12.6"/>
                    <measurement group_id="B3" value="45.4" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Oxygen use at baseline</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Oxygen User</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-oxygen user</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Pack years smoking</title>
          <units>pack years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="27.1"/>
                    <measurement group_id="B2" value="52.0" spread="27.6"/>
                    <measurement group_id="B3" value="53.4" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Current Smoker</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Current Smoker</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Vaccine Naive</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Vaccine Naive</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Previously Vaccinated</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Serotype Opsonization Titers</title>
        <description>Opsonophagocytosis activity (OPK) serotype specific geometric means</description>
        <time_frame>Measured at Baseline, Months 1, 12, and 24</time_frame>
        <population>All participants with blood samples were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Pneumovax (PPSV23)</title>
            <description>pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)</description>
          </group>
          <group group_id="O2">
            <title>Prevnar (PCV7)</title>
            <description>diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype Opsonization Titers</title>
          <description>Opsonophagocytosis activity (OPK) serotype specific geometric means</description>
          <population>All participants with blood samples were analyzed.</population>
          <units>titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.85" lower_limit="7.46" upper_limit="15.79"/>
                    <measurement group_id="O2" value="12.63" lower_limit="8.15" upper_limit="19.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132.51" lower_limit="79.78" upper_limit="220.09"/>
                    <measurement group_id="O2" value="908.23" lower_limit="609.84" upper_limit="1352.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.79" lower_limit="35.58" upper_limit="107.34"/>
                    <measurement group_id="O2" value="268.52" lower_limit="157.82" upper_limit="456.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.12" lower_limit="38.15" upper_limit="125.23"/>
                    <measurement group_id="O2" value="236.89" lower_limit="134.53" upper_limit="417.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.26" lower_limit="20.7" upper_limit="53.45"/>
                    <measurement group_id="O2" value="49.76" lower_limit="31.4" upper_limit="78.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="388.08" lower_limit="231.39" upper_limit="650.89"/>
                    <measurement group_id="O2" value="1003.30" lower_limit="653.40" upper_limit="1540.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293.06" lower_limit="129.54" upper_limit="405.80"/>
                    <measurement group_id="O2" value="476.15" lower_limit="293.06" upper_limit="773.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="240.32" lower_limit="126.30" upper_limit="457.28"/>
                    <measurement group_id="O2" value="322.98" lower_limit="184.43" upper_limit="565.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.17" lower_limit="22.25" upper_limit="62.08"/>
                    <measurement group_id="O2" value="31.44" lower_limit="19.72" upper_limit="50.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267.34" lower_limit="165.45" upper_limit="431.96"/>
                    <measurement group_id="O2" value="734.52" lower_limit="488.94" upper_limit="1103.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="142.22" lower_limit="81.86" upper_limit="247.10"/>
                    <measurement group_id="O2" value="443.55" lower_limit="283.80" upper_limit="693.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="219.35" lower_limit="122.65" upper_limit="392.28"/>
                    <measurement group_id="O2" value="432.85" lower_limit="258.03" upper_limit="726.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138.61" lower_limit="76.62" upper_limit="250.75"/>
                    <measurement group_id="O2" value="116.90" lower_limit="63.07" upper_limit="216.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1895.17" lower_limit="1207.15" upper_limit="2975.32"/>
                    <measurement group_id="O2" value="2584.06" lower_limit="1728.32" upper_limit="3863.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="839.72" lower_limit="493.8" upper_limit="1427.96"/>
                    <measurement group_id="O2" value="1801.11" lower_limit="1158.45" upper_limit="2800.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="594.09" lower_limit="357.99" upper_limit="985.91"/>
                    <measurement group_id="O2" value="1255.24" lower_limit="786.00" upper_limit="2004.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.32" lower_limit="25.25" upper_limit="70.93"/>
                    <measurement group_id="O2" value="42.81" lower_limit="26.18" upper_limit="70.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="544.49" lower_limit="334.23" upper_limit="887.02"/>
                    <measurement group_id="O2" value="1815.99" lower_limit="1217.04" upper_limit="2709.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="284.41" lower_limit="170.67" upper_limit="473.97"/>
                    <measurement group_id="O2" value="665.09" lower_limit="447.27" upper_limit="988.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267.94" lower_limit="151.74" upper_limit="473.14"/>
                    <measurement group_id="O2" value="540.01" lower_limit="361.42" upper_limit="806.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.71" lower_limit="8.40" upper_limit="22.38"/>
                    <measurement group_id="O2" value="16.86" lower_limit="10.31" upper_limit="27.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="266.49" lower_limit="155.07" upper_limit="457.97"/>
                    <measurement group_id="O2" value="193.62" lower_limit="110.85" upper_limit="338.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F 1-year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116.35" lower_limit="65.51" upper_limit="206.66"/>
                    <measurement group_id="O2" value="85.87" lower_limit="47.26" upper_limit="156.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134.21" lower_limit="77.52" upper_limit="232.36"/>
                    <measurement group_id="O2" value="116.40" lower_limit="64.04" upper_limit="211.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.79" lower_limit="7.59" upper_limit="18.33"/>
                    <measurement group_id="O2" value="18.35" lower_limit="11.34" upper_limit="29.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="114.86" lower_limit="64.88" upper_limit="203.35"/>
                    <measurement group_id="O2" value="1170.32" lower_limit="700.32" upper_limit="1955.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.75" lower_limit="26.09" upper_limit="87.38"/>
                    <measurement group_id="O2" value="407.11" lower_limit="238.14" upper_limit="695.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.97" lower_limit="22.63" upper_limit="70.60"/>
                    <measurement group_id="O2" value="266.16" lower_limit="140.25" upper_limit="505.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serotype-specific Immunoglobulin G (IgG) Antibody Levels</title>
        <description>Serotype-specific immunoglobulin G Geometric Mean IgG antibody levels (ug/ml)</description>
        <time_frame>Measured at Baseline, Months 1, 12, and 24</time_frame>
        <population>All participants with blood samples were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Pneumovax (PPSV23)</title>
            <description>pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)</description>
          </group>
          <group group_id="O2">
            <title>Prevnar (PCV7)</title>
            <description>diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose</description>
          </group>
        </group_list>
        <measure>
          <title>Serotype-specific Immunoglobulin G (IgG) Antibody Levels</title>
          <description>Serotype-specific immunoglobulin G Geometric Mean IgG antibody levels (ug/ml)</description>
          <population>All participants with blood samples were analyzed.</population>
          <units>ug/ml</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="90"/>
                <count group_id="O2" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Serotype 4 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.30" lower_limit="0.23" upper_limit="0.38"/>
                    <measurement group_id="O2" value="0.28" lower_limit="0.21" upper_limit="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.74" lower_limit="0.54" upper_limit="1.01"/>
                    <measurement group_id="O2" value="1.95" lower_limit="1.39" upper_limit="2.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.43" lower_limit="0.31" upper_limit="0.60"/>
                    <measurement group_id="O2" value="0.70" lower_limit="0.50" upper_limit="0.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 4 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45" lower_limit="0.32" upper_limit="0.65"/>
                    <measurement group_id="O2" value="0.53" lower_limit="0.38" upper_limit="0.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" lower_limit="0.73" upper_limit="1.09"/>
                    <measurement group_id="O2" value="0.90" lower_limit="0.72" upper_limit="1.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.26" lower_limit="1.65" upper_limit="3.09"/>
                    <measurement group_id="O2" value="3.19" lower_limit="2.35" upper_limit="4.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" lower_limit="1.02" upper_limit="1.72"/>
                    <measurement group_id="O2" value="1.77" lower_limit="1.29" upper_limit="2.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 6B 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.27" lower_limit="0.95" upper_limit="1.69"/>
                    <measurement group_id="O2" value="1.33" lower_limit="0.95" upper_limit="1.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" lower_limit="0.64" upper_limit="1.07"/>
                    <measurement group_id="O2" value="0.78" lower_limit="0.60" upper_limit="1.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.72" lower_limit="1.98" upper_limit="3.72"/>
                    <measurement group_id="O2" value="4.87" lower_limit="3.64" upper_limit="6.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.53" lower_limit="1.11" upper_limit="2.09"/>
                    <measurement group_id="O2" value="2.15" lower_limit="1.59" upper_limit="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 9V 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" lower_limit="0.98" upper_limit="1.90"/>
                    <measurement group_id="O2" value="1.65" lower_limit="1.22" upper_limit="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.59" lower_limit="1.87" upper_limit="3.57"/>
                    <measurement group_id="O2" value="2.53" lower_limit="1.77" upper_limit="3.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.80" lower_limit="7.47" upper_limit="15.61"/>
                    <measurement group_id="O2" value="15.73" lower_limit="11.25" upper_limit="22.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.76" lower_limit="3.97" upper_limit="8.35"/>
                    <measurement group_id="O2" value="7.47" lower_limit="5.15" upper_limit="10.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 14 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.82" lower_limit="3.38" upper_limit="6.88"/>
                    <measurement group_id="O2" value="5.68" lower_limit="3.75" upper_limit="8.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.16" lower_limit="0.88" upper_limit="1.53"/>
                    <measurement group_id="O2" value="1.07" lower_limit="0.78" upper_limit="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" lower_limit="3.11" upper_limit="5.82"/>
                    <measurement group_id="O2" value="9.65" lower_limit="7.22" upper_limit="12.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="1.59" upper_limit="3.19"/>
                    <measurement group_id="O2" value="3.74" lower_limit="2.78" upper_limit="5.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 18C 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" lower_limit="1.38" upper_limit="2.72"/>
                    <measurement group_id="O2" value="2.77" lower_limit="2.05" upper_limit="3.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.20" lower_limit="2.62" upper_limit="3.91"/>
                    <measurement group_id="O2" value="3.01" lower_limit="2.45" upper_limit="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.79" lower_limit="5.27" upper_limit="8.76"/>
                    <measurement group_id="O2" value="7.54" lower_limit="5.76" upper_limit="9.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F 1-year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.25" lower_limit="3.26" upper_limit="5.53"/>
                    <measurement group_id="O2" value="4.32" lower_limit="3.37" upper_limit="5.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 19F 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85" lower_limit="2.90" upper_limit="5.11"/>
                    <measurement group_id="O2" value="3.68" lower_limit="2.74" upper_limit="4.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.58" lower_limit="0.45" upper_limit="0.75"/>
                    <measurement group_id="O2" value="0.74" lower_limit="0.56" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F 1-Month</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.88" lower_limit="1.29" upper_limit="2.73"/>
                    <measurement group_id="O2" value="7.76" lower_limit="5.49" upper_limit="10.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F 1-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" lower_limit="0.80" upper_limit="1.55"/>
                    <measurement group_id="O2" value="2.73" lower_limit="1.94" upper_limit="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serotype 23F 2-Year</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.72" upper_limit="1.39"/>
                    <measurement group_id="O2" value="1.99" lower_limit="1.38" upper_limit="2.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 Years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pneumovax (PPSV23)</title>
          <description>pneumococcal capsular polysaccharide vaccine (PPSV23) (Pneumovax)</description>
        </group>
        <group group_id="E2">
          <title>Prevnar (PCV7)</title>
          <description>diphtheria protein-conjugated vaccine (PCV7) (Prevnar) 1.0 mL dose</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ischemic Heart Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Other Heart Disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal Insufficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Hypercalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Liver Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Death Unkown Cause</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Intestinal Infectious Disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Complication from surgery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Multiple drug intoxication</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropy</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Osteopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Oral Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Digestive Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Respiratory Neoplasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Benign or Uncertain Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Brain Neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Neuroendocrine Neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Inflammatory diseases of prostate</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="90"/>
                <counts group_id="E2" events="14" subjects_affected="11" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Other Respiratory</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="90"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Pulmonary Circulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Atherosclerosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="90"/>
                <counts group_id="E2" subjects_affected="54" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Sprains</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Rheumatism</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="90"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Benign or Uncertain Neoplasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="90"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Respiratory Infection</sub_title>
                <counts group_id="E1" events="18" subjects_affected="15" subjects_at_risk="90"/>
                <counts group_id="E2" events="19" subjects_affected="15" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>COPD</sub_title>
                <counts group_id="E1" events="84" subjects_affected="40" subjects_at_risk="90"/>
                <counts group_id="E2" events="74" subjects_affected="36" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Other - Respiratory</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="90"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin - Inflammatory</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="90"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sarah Harnden</name_or_title>
      <organization>University of Minnesota</organization>
      <phone>612-626-9011</phone>
      <email>sharnden@ccbr.umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

